i
Interim clinical considerations for use of COVID-19 vaccines currently approved or authorized in the United States
-
Aug. 31, 2021
Details:
-
Corporate Authors:
-
Content Notes:Background -- Age groups approved or authorized to receive COVID-19 vaccine by vaccine product -- COVID-19 vaccine administration -- Interchangeability of COVID-19 vaccine products -- People vaccinated for COVID-19 outside the United States -- People vaccinated for COVID-19 as part of a clinical trial in the United States -- Coadministration of COVID-19 vaccines with other vaccines -- COVID-19 vaccination and SARS-CoV-2 infection -- Antiviral therapy and COVID-19 vaccination -- Vaccinating people with a known COVID-19 exposure or during COVID-19 outbreaks -- Considerations for use of an additional dose of COVID-19 vaccine following a primary vaccine series -- Considerations for use of an additional mRNA COVID-19 vaccine dose after an initial 2-dose COVID-19 mRNA vaccine series for immunocompromised people -- Considerations for vaccination of people with certain underlying medical conditions -- Considerations for use of the Janssen COVID-19 vaccine in certain populations -- Considerations involving pregnancy, lactation, and fertility -- Vaccination of children and adolescents -- Patient counseling -- Contraindications and precautions -- Reporting of vaccine adverse events -- Laboratory testing -- Appendix A. Vaccine administration errors and deviations -- Appendix B: Triage of people with a history of allergies or allergic reactions -- Appendix C: Ingredients included in COVID-19 vaccines -- Appendix D: Potential characteristics of allergic reactions, vasovagal reactions, and vaccine side effects following COVID-19 vaccination -- References -- Previous Updates.
-
Subjects:
-
Document Type:
-
Place as Subject:
-
Collection(s):
-
Main Document Checksum:
-
Download URL:
-
File Type: